Last data update: Jan 13, 2025. (Total: 48570 publications since 2009)
Records 1-4 (of 4 Records) |
Query Trace: Clarke TC[original query] |
---|
Guidance for selecting model options in the National Cancer Institute Joinpoint Regression Software
Irimata KE , Bastian BA , Clarke TC , Curtin SC , Badwe R , Rui P . Vital Health Stat 1 2022 (194) 1-22 The purpose of this report is to provide guidance to users of NCHS data in the selection of modeling options when using the NCI Joinpoint regression software to analyze trends. This report complements another report, "National Center for Health Statistics Guidelines for Analysis of Trends." Considerations are presented for selecting the modeling options, with examples illustrating the choices. The tradeoffs and consequences of choosing the various modeling options using data from NCHS data systems are discussed.encounters. |
Cancer screening test use-U.S., 2019
Sabatino SA , Thompson TD , White MC , Shapiro JA , Clarke TC , Croswell JM , Richardson LC . Am J Prev Med 2022 63 (3) 431-439 INTRODUCTION: The U.S. Preventive Services Task Force recommends breast, cervical, and colorectal cancer screening to reduce mortality from these cancers, but screening use has been below national targets. The purpose of this study is to examine the proportion of screening-eligible adults who are up to date with these screenings and how screening use compares with Healthy People 2020 targets. METHODS: Data from the 2019 National Health Interview Survey were used to examine the percentages of adults up to date with breast cancer screening among women aged 5074 years without previous breast cancer, cervical cancer screening among women aged 2165 years without previous cervical cancer or hysterectomy, and colorectal cancer screening among adults aged 5075 years without previous colorectal cancer. Estimates are presented by sociodemographic characteristics and healthcare access factors. Analyses were conducted in 2021. RESULTS: Percentages of adults up to date were 76.2% (95% CI= 75.0, 77.5) for breast cancer screening, 76.4% (95% CI= 75.2, 77.6) for cervical cancer screening, and 68.3% (95% CI= 67.3, 69.3) for colorectal cancer screening. Although some population subgroups met breast and colorectal cancer screening targets (81.1% and 70.5%, respectively), many did not, and cervical cancer screening was below the target for all examined subgroups. Lower education and income, nonmetropolitan county of residence (which included rural counties), no usual source of care or health insurance coverage, and Medicaid coverage were associated with lower screening test use. CONCLUSIONS: Estimated use of breast, cervical, and colorectal cancer screening tests based on the 2019 National Health Interview Survey were below national targets. Continued monitoring may allow for examination of screening trends, inform interventions, and track progress in eliminating disparities. |
Screening for colorectal cancer in the United States: correlates and time trends by type of test
Shapiro JA , Soman AV , Berkowitz Z , Fedewa SA , Sabatino SA , de Moor JS , Clarke TC , Doria-Rose VP , Breslau ES , Jamal A , Nadel MR . Cancer Epidemiol Biomarkers Prev 2021 30 (8) 1554-1565 BACKGROUND: It is strongly recommended that adults aged 50-75 years be screened for colorectal cancer (CRC). Recommended screening options include colonoscopy, sigmoidoscopy, computed tomography colonography, guaiac fecal occult blood testing (FOBT), fecal immunochemical testing (FIT), or the more recently introduced FIT-DNA (FIT in combination with a stool DNA test). CRC screening programs can benefit from knowledge of patterns of use by test type and within population subgroups. METHODS: Using 2018 National Health Interview Survey data, we examined CRC screening test use for adults aged 50-75 years (N=10,595). We also examined time trends in CRC screening test use from 2010-2018. RESULTS: In 2018, an estimated 66.9% of U.S. adults aged 50-75 years had a CRC screening test within recommended time intervals. However, the prevalence was less than 50% among those aged 50-54 years, those without a usual source of health care, those with no doctor visits in the past year, and those who were uninsured. The test types most commonly used within recommended time intervals were colonoscopy within 10 years (61.1%), FOBT or FIT in the past year (8.8%), and FIT-DNA within 3 years (2.7%). After age-standardization to the 2010 census population, the percentage up-to-date with CRC screening increased from 61.2% in 2015 to 65.3% in 2018, driven by increased use of stool testing, including FIT-DNA. CONCLUSIONS: These results show some progress, driven by a modest increase in stool testing. However, CRC testing remains low in many population subgroups. IMPACT: These results can inform efforts to achieve population CRC screening goals. |
The use of complementary health approaches among U.S. adults with a recent cancer diagnosis
Clarke TC . J Altern Complement Med 2017 24 (2) 139-145 OBJECTIVE: The object of this study was to explore the use of complementary health approaches among U.S. adults with a cancer diagnosis in the past 5 years and distinguish use for general wellness from use specifically for treatment. METHODS: Using data from the 2002, 2007, and 2012 National Health Interview Survey, the study included 1359 persons with a cancer diagnosis of selected cancers in the past 5 years. Participants were asked about their use of complementary health approaches for general reasons and cancer treatment in the past 12 months. Responses were aggregated into the use of any complementary approach as well as examined by mode of practice. RESULTS: Overall, 35.3% of persons with a cancer diagnosis used complementary health approaches in the past 12 months. These persons were more likely to have used a biologically based approach (22.8%) compared with other approaches. Persons with breast cancer were significantly more likely to use any complementary health approach (43.6%) compared with those with other recently diagnosed cancers. Few persons with a cancer history (2.3%) used complementary approaches specifically for cancer treatment. However, prevalence of use for treatment varied by cancer type (0.4%-6.8%). CONCLUSIONS: This study highlights differences in the use of various types of complementary health approaches for different reasons among persons with recent diagnoses of some of the most commonly diagnosed cancers in the United States. |
- Page last reviewed:Feb 1, 2024
- Page last updated:Jan 13, 2025
- Content source:
- Powered by CDC PHGKB Infrastructure